Protalix BioTherapeutics to Present at the 2024 BIO International Convention

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [3] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [3] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product for Gaucher disease, to Pfizer Inc., retaining full rights in Brazil [3] Product Pipeline - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [3] - The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [4] - The development pipeline includes PRX–115, a recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a long-acting DNase I for NETs-related diseases, among others [4] Industry Context - The BIO International Convention is the largest industry gathering for biotechnology and biopharmaceutical leaders, providing networking and partnering opportunities [2][5] - The event will take place from June 3-6, 2024, in San Diego, California, where Protalix's CEO will present corporate updates [1]